Liquid biopsy to tailor the treatment of advanced hormone receptor-positive breast cancer in the era of novel endocrine agents and CDK4/6-inhibitors.
作者信息
Seguí Elia, Schettini Francesco
机构信息
SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
出版信息
Ann Transl Med. 2024 Feb 1;12(1):19. doi: 10.21037/atm-23-1804. Epub 2023 Oct 30.
Abstract
摘要
相似文献
1
Liquid biopsy to tailor the treatment of advanced hormone receptor-positive breast cancer in the era of novel endocrine agents and CDK4/6-inhibitors.在新型内分泌药物和CDK4/6抑制剂时代，液体活检用于定制晚期激素受体阳性乳腺癌的治疗方案。
Ann Transl Med. 2024 Feb 1;12(1):19. doi: 10.21037/atm-23-1804. Epub 2023 Oct 30.
2
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR/HER2 Breast Cancer.晚期 HR/HER2 乳腺癌患者在接受 CDK4/6 抑制剂和内分泌治疗进展后的实用治疗策略和未来方向。
Clin Breast Cancer. 2020 Feb;20(1):1-11. doi: 10.1016/j.clbc.2019.06.017. Epub 2019 Aug 23.
3
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂克服转移性乳腺癌患者中与雌激素受体1（ESR1）突变相关的内分泌耐药性。
Cancers (Basel). 2023 Feb 18;15(4):1306. doi: 10.3390/cancers15041306.
4
[Therapeutic strategies for the treatment of endocrine resistant hormone receptor positive advanced breast cancer].[内分泌抵抗性激素受体阳性晚期乳腺癌的治疗策略]
Bull Cancer. 2023 Jan;110(1):69-87. doi: 10.1016/j.bulcan.2022.09.007. Epub 2022 Oct 25.
5
Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.CDK4/6抑制剂联合内分泌治疗晚期激素受体阳性（HR+）和人表皮生长因子受体2阴性（HER2-）乳腺癌的药物经济学评价：一项系统综述
Ann Transl Med. 2022 Feb;10(4):233. doi: 10.21037/atm-21-5110.
6
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.CDK4/6抑制剂：乳腺癌中的耐药机制及反应性潜在生物标志物
Future Oncol. 2022 Mar;18(9):1143-1157. doi: 10.2217/fon-2021-0842. Epub 2022 Feb 9.
7
Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.CDK4/6 抑制剂联合内分泌治疗与单独内分泌治疗用于激素受体阳性、HER2 阴性晚期乳腺癌的疗效和安全性：系统评价和荟萃分析。
Ann Palliat Med. 2022 Dec;11(12):3727-3742. doi: 10.21037/apm-22-1306.
8
Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.巴泽昔芬联合帕博西利治疗晚期激素受体阳性乳腺癌的 I/II 期临床疗效及液体活检的全外显子组测序结果
Clin Cancer Res. 2022 Dec 1;28(23):5066-5078. doi: 10.1158/1078-0432.CCR-22-2305.
9
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.激素敏感型晚期乳腺癌患者内分泌治疗类型与雌激素受体 1 突变发展的相关性：一项随机和非随机试验的系统评价和荟萃分析。
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21.
10
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.液体活检中检测到的 PI3K 突变与转移性乳腺癌患者对 CDK4/6 抑制剂的敏感性降低有关。
Pharmacol Res. 2021 Jan;163:105241. doi: 10.1016/j.phrs.2020.105241. Epub 2020 Oct 10.
引用本文的文献
1
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.基于二代测序对实体瘤基因组改变可干预情况的评估：“莫扎特”前瞻性观察研究
Oncologist. 2025 Jan 17;30(1). doi: 10.1093/oncolo/oyae206.
2
Editorial: Diagnostic, prognostic and predictive factors of response in the era of precision oncology in breast cancer.社论：乳腺癌精准肿瘤学时代反应的诊断、预后和预测因素
Front Oncol. 2023 Nov 23;13:1337315. doi: 10.3389/fonc.2023.1337315. eCollection 2023.
本文引用的文献
1
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.高危早期 HER2 阴性乳腺癌患者接受新辅助化疗时循环肿瘤 DNA 的临床意义和生物学特性。
Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4.
2
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.激素受体阳性转移性乳腺癌中内在亚型的预后价值：系统评价和荟萃分析。
ESMO Open. 2023 Jun;8(3):101214. doi: 10.1016/j.esmoop.2023.101214. Epub 2023 Apr 17.
3
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.接受来曲唑联合瑞博西利治疗的 HR 阳性/HER2 阴性晚期乳腺癌患者的血清胸苷激酶活性：来自前瞻性 BioItaLEE 试验的结果。
Eur J Cancer. 2023 Jun;186:1-11. doi: 10.1016/j.ejca.2023.03.001. Epub 2023 Mar 8.
4
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.循环肿瘤 DNA 揭示转移性乳腺癌中具有临床相关性的复杂生物学特征。
Nat Commun. 2023 Mar 1;14(1):1157. doi: 10.1038/s41467-023-36801-9.
5
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy.PI3K抑制剂在癌症治疗中的现状与未来挑战
Cancers (Basel). 2023 Jan 23;15(3):703. doi: 10.3390/cancers15030703.
6
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer.激素受体阳性且人表皮生长因子受体2阴性转移性乳腺癌中内在分子亚型的临床意义
Cancer Treat Rev. 2023 Jan;112:102496. doi: 10.1016/j.ctrv.2022.102496. Epub 2022 Dec 9.
7
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report.激素受体阳性/人表皮生长因子受体2阴性伴内脏危象的转移性乳腺癌的内在亚型及治疗决策：一例报告
Front Oncol. 2022 Nov 8;12:1009352. doi: 10.3389/fonc.2022.1009352. eCollection 2022.
8
Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.巴泽昔芬联合帕博西利治疗晚期激素受体阳性乳腺癌的 I/II 期临床疗效及液体活检的全外显子组测序结果
Clin Cancer Res. 2022 Dec 1;28(23):5066-5078. doi: 10.1158/1078-0432.CCR-22-2305.
9
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.在接受芳香化酶抑制剂和帕博西利治疗期间 ESR1 突变升高的晚期乳腺癌中，转为氟维司群联合帕博西利与不转换相比（PADA-1）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29.
10
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment.将新型口服选择性雌激素受体降解剂纳入乳腺癌治疗。
Curr Opin Oncol. 2022 Nov 1;34(6):635-642. doi: 10.1097/CCO.0000000000000892. Epub 2022 Aug 24.
Zotero 插件